483
KBI Biopharma, Inc.KBI Biopharma, Inc. – FDA 483, Mar 2, 2020
Record Details
KBI Biopharma, Inc. in Boulder, Colorado was inspected from March 2-6, 2020, and received one observation. The inspection revealed that a characterization study performed to evaluate pegfilgrastim drug substance did not meet system suitability criteria. This failure invalidated the final quality control analytical results, indicating a potential issue with analytical method control.
View Company Profile
ID · a75c9695-e699-443b-997c-1d7fc59b8dd4
Other documents for KBI Biopharma, Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.